A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- BriaCell Therapeutics Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT06471673
- Locations
- ๐บ๐ธ
Sarcoma Oncology Center, Santa Monica, California, United States
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- BriaCell Therapeutics Corporation
- Target Recruit Count
- 404
- Registration Number
- NCT06072612
- Locations
- ๐บ๐ธ
Sheboygan Cancer & Blood Specialists, Sheboygan, Wisconsin, United States
๐บ๐ธHoag Hospital Center, Irvine, California, United States
๐บ๐ธHoag Hospital Irvine, Irvine, California, United States
Combination Study of SV-BR-1-GM With Retifanlimab
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- BriaCell Therapeutics Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT03328026
- Locations
- ๐บ๐ธ
Nebraska Cancer Specialists, Omaha, Nebraska, United States
๐บ๐ธSt. Joseph Heritage Healthcare, Santa Rosa, California, United States
๐บ๐ธSt Vincent-Frontier Cancer Center, Billings, Montana, United States
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- BriaCell Therapeutics Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT03066947
- Locations
- ๐บ๐ธ
St. Joseph Heritage Healthcare, Santa Rosa, California, United States
๐บ๐ธUniversity of Miami/Sylvester at Plantation, Plantation, Florida, United States
๐บ๐ธCancer Center of Kansas (CCK), Wichita, Kansas, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath